THURSDAY, Sept. 12, 2024 -- For patients with resectable non-small-cell lung cancer (NSCLC), perioperative nivolumab is associated with event-free...

FRIDAY, Sept. 13, 2024 -- Tusamitamab ravtansine (tusa rav), an immunoconjugate, does not improve progression-free survival (PFS) in patients with...

THURSDAY, Sept. 12, 2024 -- The overall second primary malignancy (SPM) point estimate was 5.8 percent for patients receiving chimeric antigen...

TUESDAY, Sept. 17, 2024 -- The delivery of early, virtual palliative care has similar effects on quality of life as in-person care in patients with...

THURSDAY, Sept. 5, 2024 -- For patients with metastatic or surgically unresectable leiomyosarcoma, combination therapy with doxorubicin and...

THURSDAY, Sept. 5, 2024 -- Lung function remains stable over three years after hematopoietic cell transplant (HCT) among patients with sickle cell...

THURSDAY, Sept. 12, 2024 -- For patients with locally advanced rectal cancer pursuing organ preservation, long-course chemoradiotherapy (LCCRT) is...

THURSDAY, Sept. 12, 2024 -- For patients with locally advanced rectal cancer pursuing organ preservation, long-course chemoradiotherapy (LCCRT) is...

FRIDAY, Sept. 6, 2024 -- The risk for lung cancer is high in patients with rheumatoid arthritis (RA) and pulmonary complications, according to a study...

THURSDAY, Sept. 19, 2024 -- For patients with advanced melanoma, there is a survival benefit for nivolumab plus ipilimumab and for nivolumab...